Background
Prostaglandin E 2 plays a crucial role in inflammation, including pain, fever and tumorigenesis. Inflammatory cells, fibroblasts and epithelium are the main source of PGE 2 throughout an immune response. There are four known receptors for PGE 2 , E type prostanoid receptors 1-4 (EP 1,2,3,4 ). According to recent reports, the EP 4 receptor seems to be a potential target of therapeutic treatment for attenuating inflammation as well as increased endothelial permeability.
Methods
Primary human microvascular endothelial cells of the lung (HMVEC-L) were cultured and transfected using siRNA approach. The mRNA level of the EP 4 receptor was determined using RT-PCR. EP 4 receptor protein expression was evaluated via Western blotting and flow cytometry. Changes in electrical impedance were measured using an ECIS application. Morphological alterations were observed via immunofluorescent staining of β-catenin and F-actin. Cell cycle and apoptosis analysis were performed using flow cytometry.
Results
The pulmonary microvascular endothelial cells express the PGE 2 receptor EP 4 , which was shown by flow cytometry and Western blotting. In endothelial cells, EP 4 receptor protein expression was down-regulated to less than 40% by using the siRNA transfection approach. Also, the mRNA level of the EP 4 receptor was significantly down-regulated below 15% using siRNA transfection. In the endothelial impedance measurements, the EP 4 agonist and PGE 2 -induced barrier enhancement was significantly suppressed in EP 4 receptor-silenced cells. Morphological studies revealed that the thrombininduced disruption of endothelial monolayers could be reversed by stimulation of EP 4 receptors. Cell-cell contacts were enhanced and stress fibre formation was prevented by pre-treatment with PGE 2 and an EP 4 -selective agonist. PGE 2 and the EP 4 agonist did not induce any changes in the endothelial cell cycle; however, EP 4 receptor activation appeared to be protective against staurosporine-induced apoptosis. Apoptotic cells were determined in the sub-G 1 phase of the cell cycle.
Conclusions
These data suggest EP 4 receptor agonists as potential therapeutic intervention for diseases with increased vascular permeability such as acute lung injury.
